With the rise of decentralized trials comes a focus on patient-centricity, but what does that look like holistically? Trishna Bharadia joins us to discuss the considerations you need to make when applying the patient perspective to clinical trial design. This episode will cover dynamic survey design, informed consent, patient diversity, and patient safety as they relate to achieving true patient-centricity in your studies.

Constantly changing regulations and a multitude of new endpoints continue to keep clinical researchers on their toes. While these regulations and endpoints are designed to keep patients safe, they often create unintended barriers that keep patients out of clinical trials. In this episode, we discuss with Kafayat Babajide, Director of Patient Insights & Experience with Johnson and Johnson, the ways in which a patient-centric approach can remove controllable barriers from the clinical trial process and strengthen your patient engagement.

Approximately 39.5% of all men and women will be diagnosed with cancer at some point during their lifetimes, and yet only 8% of oncology patients participate in clinical trials. Many industry leaders think that a greater focus on patient advocacy could be the missing link.In this episode, Rose Gerber, Director of Patient Advocacy and Education at the Community Oncology Alliance – once a patient herself and now a dedicated advocate – will share her story and discuss how patient advocacy is helping to increase patient enrollment in clinical trials across every therapeutic area.

Reducing the number of vendors you interact with allows you to not only achieve higher quality data, you can also spend more time focusing on what matters- the patients. Our fully integrated RTSM and EDC allows you to spend more time focused on your data and less on outside programmers and  vendors.  In this episode we will explore the value of a combined solution and what you can expect in return.

It’s no secret that the United States has documented disparities in morbidity and mortality rates among racial/ethnic minority groups and those of lower socioeconomic status. More recently we’ve seen a disproportionate amount of African Americans affected by COVID-19, but they have been underrepresented in clinical research. In this podcast we are joined by Kimberly Richardson, Patient Advocate and Cancer Survivor, to discuss how we can work towards achieving health equity in the United States, what steps can be taken today, and the impact this would have on clinical research and underserved communities.

Patients are no longer passive research subjects, but rather being integrated into the research process from the start. Patient advocates help with such integrations, from protocol design through to clinical trial findings. It has been proven that designing clinical trials to meet the patient needs facilitates better patient adherence and reduces patient drop out rates.  But more importantly, advocating for a patient is advocating for a human being, not a test subject. As clinical research evolves more emphasis has been placed on patient experience, rather than just data points. Listen to discover how a patient advocate, Susan Stein, MPH, advances patient care, brings the patient voice and insights into discussions and organizational decision making. 

ClinData is a leading South African CRO focused on Animal Health studies, they recently eradicated paper from 21 studies with plans to move more to electronic data capture going forward. In this podcast we’ll discuss how ClinData succeeded in making the switch from paper to EDC and the benefits of this change for animal health studies.

Phastar and Medrio have been partnering together on trials for the past 3 years, culminating in a unique way to visualize clinical trial data. Through the use of Medrio’s API, Phastar has built a data visualization tool that reduces risk and allows for complete study oversight. In this podcast we’ll discuss the need for data visualization in clinical trials, how Phastar has continued their trials during a global pandemic, and what their thoughts are on the future of how we collect and view data. 

Quartesian and Medrio have had a solid partnership since 2010 and have partnered together in over 150 studies. In this podcast, we’ll discuss the foundation of our successful partnership, eSource, and the innovative ways we are collaborating with Quarteisan on a COVID-19 study currently underway.

Welcome to the Trial Talks podcast, a thought-provoking show about clinical research. On this podcast, we will be exploring trends in the industry as well as the changing landscape, pandemic impact, various types of research, and more. Today, I’ll be talking with Donna Chang, the CEO and founder of Hope Biosciences. Hope Biosciences focuses on stem cell research to prevent disease and degeneration. In this episode we will be talking about the progress that has been made in the last decade, with regards to stem cell research. We’ll also be talking about stem cell research and COVID-19.  Talking Points: What is Donna Chang’s background and how did Hope Biosciences start? What has been happening in stem cell research in the last 5 - 10 years? The Golden Age of Life Sciences How this research applies to COVID-19 Getting studies up and running for COVID-19 (and other challenges) Other studies and trials that Hope Biosciences is working on The future trends of trials and the long term goals for Hope Biosciences Resources/Links: Official website: Hope Biosciences

Due to COVID-19 the clinical trial industry has been adopting advanced clinical trial technology at warp speed, but what does this mean for the future? What is a sustainable approach to ensure the industry does not face the same challenges and delays should we be impacted by another pandemic or global crisis? In this podcast we sit down with Mary Mattes, Senior Vice President of Global Operations at Synteract to discuss decentralization of clinical trials and a hybrid model.

Australia and New Zealand have not been impacted as much as North America and the EU with regards to COVID-19. For this reason, and their quick study-start timelines, this region could become very attractive to sponsors in the near future. In this podcast, Yvonne Lungershausen and Sandrien Louwaars discuss how Avance Clinical prepared for the pandemic, what tools they implemented that allowed trial continuation, and why clinical trials are currently thriving in the region.